Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Prevalence of viral respiratory tract infections in children with asthma

Nino Khetsuriani, MD, PhD, a N. Neely Kazerouni, DrPH, b Dean D. Erdman, DrPH, a Xiaoyan Lu, MS,a Stephen C. Redd, MD,b Larry J. Anderson, MD, a and W. Gerald Teague, MD a Atlanta, Ga

Background: Previous studies support a strong association between viral respiratory tract infections and asthma exacerbations. The effect of newly discovered viruses on asthma control is less well defined.

Objective: We sought to determine the contribution of respiratory viruses to asthma exacerbations in children with a panel of PCR assays for common and newly discovered respiratory viruses.

Methods: Respiratory specimens from children aged 2 to 17 years with asthma exacerbations (case patients, n = 65) and with well-controlled asthma (control subjects, n = 77), frequency matched by age and season of enrollment, were tested for rhinoviruses, enteroviruses, respiratory syncytial virus, human metapneumovirus, coronaviruses 229E and OC43, parainfluenza viruses 1 to 3, influenza viruses, adenoviruses, and human bocavirus.

Results: Infection with respiratory viruses was associated with asthma exacerbations (63.1% in case patients vs 23.4% in control subjects; odds ratio, 5.6; 95% CI, 2.7-11.6). Rhinovirus was by far the most prevalent virus (60% among case patients vs 18.2% among control subjects) and the only virus significantly associated with exacerbations (odds ratio, 6.8; 95% CI, 3.2-14.5). However, in children without clinically manifested viral respiratory tract illness, the prevalence of rhinovirus infection was similar in case patients (29.2%) versus control subjects (23.4%; P > .05). Other viruses detected included human metapneumovirus (4.6% in patients with acute asthma vs 2.6% in control subjects), enteroviruses (4.6% vs 0%), coronavirus 229E (0% vs 1.3%), and respiratory syncytial virus (1.5% vs 0%).

Conclusion: Symptomatic rhinovirus infections are an important contributor to asthma exacerbations in children.

Clinical implications: These results support the need for therapies effective against rhinovirus as a means to decrease asthma exacerbations. (J Allergy Clin Immunol 2007;119: 314-21.)

Key words: Respiratory viruses, asthma, asthma exacerbation, case-control study, PCR, rhinovirus

For more than 3 decades, viral respiratory tract infections have been reported as important triggers for exacerbations of asthma in adults and children.1-5 In early studies based on nonmolecular means of detection, viral infections were identified in fewer than 25% of acute asthma episodes.6-10 Results of recent studies based on PCR assays support a much greater role of viral respiratory tract infections in acute asthma.6-10

A wide range of respiratory viruses, including rhinoviruses, respiratory syncytial virus (RSV), influenza viruses, coronaviruses, human parainfluenza viruses, enteroviruses, human metapneumovirus (HMPV), and the recently discovered human bocavirus, have been detected from patients with asthma exacerbations.10-18 Rhinoviruses are currently recognized as the most common respiratory virus associated with acute asthma in school-age children, whereas RSV appears to be the most common respiratory virus associated with wheezing episodes and asthma in young children.6,9,11,12,19,20 Considering the discovery of new viruses and the recent progress in the development of drugs effective against respiratory viruses,21-25 determining the spectrum of viruses associated with asthma exacerbation and the contribution of potentially treatable agents is important in the evaluation of intervention strategies aimed at decreasing asthma morbidity.

Thus additional epidemiologic studies are necessary to better understand the relationship between respiratory viruses and asthma exacerbations. We conducted this case-control study to evaluate the extent of association of different respiratory viruses with asthma exacerbations in children using a full panel of PCR assays for respiratory viruses, including the newly discovered bocavirus.

METHODS

Study design and recruitment strategy

Pediatric patients with asthma who sought treatment at an urban children’s medical center were invited to participate in an
TABLE I. Case definitions used for the study

| Category                        | Criteria                                                                 |
|---------------------------------|---------------------------------------------------------------------------|
| Current persistent asthma       | In children aged 2-5 y, all of the following:                             |
|                                 | 1. physician diagnosis of asthma;                                         |
|                                 | 2. ≥2 previous episodes of cough, wheezing, and/or respiratory distress;   |
|                                 | 3. current treatment with asthma medications; and                         |
|                                 | 4. having a parent or sibling with a current or past diagnosis of asthma or allergy and/or having current or previous evidence of atopy, as defined by seasonal rhinitis, eczema, or food hypersensitivity. |
| Case                            | In children aged 6-17 y, all of the following:                           |
|                                 | 1. physician diagnosis of asthma;                                         |
|                                 | 2. symptoms of asthma in past 12 mo; and                                 |
|                                 | 3. current treatment with asthma medications.                            |
| Control                         | Current persistent asthma, hospital admission, or clinic visit for asthma exacerbation, and all of the following: |
|                                 | 1. presence of signs and symptoms of airflow obstruction within past 48 h (eg, cough, wheeze, shortness of breath, and chest tightness); |
|                                 | 2. increase in asthma symptoms resulting in hospital admission or clinic visit; |
|                                 | 3. repeated use of short-acting β-agonists within past 48 h; and         |
|                                 | 4. increased dose or addition of a new asthma controller therapy within past week. |
| Symptomatic acute respiratory viral illness | More than 1 of the following: fever, stuffy/runny nose, headache, muscle aches, and eye redness or pain at the time of clinic visit or hospital admission. |

Abbreviations used

HMPV: Human metapneumovirus
OR: Odds ratio
RSV: Respiratory syncytial virus

observational case-control study. The study protocol, recruiting advertisements, and consent forms were approved by the institutional review boards of Emory University School of Medicine, Children’s Healthcare of Atlanta at Egleston Hospital, and the Centers for Disease Control and Prevention. Legally authorized representatives of the children provided informed consent, and the children, when appropriate, provided assent, after which study coordinators collected clinical information and biologic specimens.

All participants fulfilled the study criteria for current persistent asthma (Table I). Participants were classified as case patients or control subjects by a physician investigator at the time of enrollment. Because of the difficulty in differentiation of asthma from wheezing episodes of other origin in very young children, the lower age limit in the study group was 2 years. Criteria for case patients and control subjects, as well as a clinically manifested respiratory tract viral illness, defined as 2 or more symptoms, are listed in Table I.

Because the capacity to detect viral respiratory infections is time sensitive relative to the onset of symptoms, participants with acute exacerbations of asthma were enrolled within 48 hours of admission to the hospital. To account for the known age-related and seasonal variations in occurrence of viral infections, we frequency matched case patients and control subjects by age and season of enrollment.

Study procedures

We obtained respiratory secretions from all participants by using nasopharyngeal and throat swabs. Respiratory specimens were held at 4°C until transport on ice pack to the virology laboratories at the Centers for Disease Control and Prevention.

Pulmonary function was measured with a calibrated spirometer (KoKo PDS; Ferraris, Louisville, Colo) from the best of 3 forced vital capacity maneuvers. The results fulfilled American Thoracic Society criteria for reproducibility and were expressed according to the reference standards of Hankinson et al.26

Identification of respiratory viruses

Respiratory swab specimens were placed in 1 mL of RNA Storage Solution (Ambion, Austin, Tex), and 200-μL aliquots of the fluid were added to NucliSens lysis buffer for automated nucleic acid extraction (bioMérieux, Durham, NC). Total nucleic acid extracts (approximately 40 μL) were supplemented with same volume RNA Storage Solution and tested immediately by using PCR or stored at −70°C.

The nucleic acid extracts were tested for picornaviruses (using primers detecting rhinoviruses and enteroviruses; RSV; HMPV; human parainfluenza viruses 1, 2, and 3; influenza viruses A and B; and adenoviruses) with a previously described PCR assay panel.27,28 In addition, all specimens were tested for human coronaviruses 229E and OC4329 and human bocavirus30 by using real-time PCR assays. To distinguish rhinoviruses from enteroviruses, amplicons from picornavirus PCR-positive samples were sequenced, and the sequences were compared with published sequences on the National Institutes of Health genetic sequence database GenBank. All nucleic acid extracts were also tested for the glyceraldehyde-3-phosphate dehydrogenase housekeeping gene to evaluate the integrity of the nucleic acid extract and to detect PCR inhibitors. The assay used for the study detected less than 10 viral target RNA transcript copies and all rhinovirus serotypes.

Data analysis

We performed bivariate analyses using χ² and Fisher exact tests to compare the prevalence of respiratory viruses and other variables...
between the study groups. Trends in proportional distribution of FEV<sub>1</sub> by viral infection and by asthma exacerbations were analyzed by using the $\chi^2$ trend test. The $t$ test statistic was used to compare mean age and FEV<sub>1</sub> (expressed as percent predicted) by asthma exacerbation status. All $P$ values were calculated on the basis of 2-sided tests.

We used multiple logistic regression analysis to model the log odds of asthma exacerbations associated with respiratory tract viral infections and to calculate estimated odds ratios (ORs) and 95% CIs. All logistic models were tested for potential confounders (eg, age, season, and sex) and effect modifiers. The final models were adjusted for factors (eg, race/ethnicity) that were not collinear and confounded the $\beta$ coefficient for the association between the respiratory tract viral infections and asthma exacerbations by 10% or more. In addition, the final model included frequency-matched variables, such as age and season. All statistical procedures were performed with SAS version 8.2 software (SAS Institute Inc, Cary, NC).

### RESULTS

During March 2003 through February 2004, 337 children with a primary diagnosis of asthma were treated at the study hospital, and 374 were treated in the pulmonary clinic. From this population, 190 were eligible to participate in the study; of these, 48 refused, and 142 enrolled. The most common reason for refusal was anxiety related to the nasal swab procedure. Sixty-five enrollees had acute asthma exacerbations, and 77 had well-controlled asthma (Table II). Of the 65 participants with acute asthma, 47 enrolled at the hospital (referred to as “hospitalized case patients”), and 18 enrolled at the pulmonary clinic (“non-hospitalized case patients”).

The comparison of frequency-matched case patients and control subjects showed that the mean time since the onset of asthma did not differ between case patients and control subjects (6 years for both). Case patients were significantly more likely than control subjects to be of African American descent, to have visited a health care provider for acute asthma 3 or more times in the past 12 months, to have been hospitalized for asthma at least twice in the past 12 months, and to have ever been admitted to the intensive care unit for asthma or to have 2 or more symptoms of a respiratory tract viral illness at enrollment (Table II). Children with acute exacerbations were more likely to have received in the past week inhaled $\beta_2$-adrenergic agonists and ipratropium bromide, whereas children with well-controlled asthma were more likely to have been treated with montelukast. The 2 groups did not differ significantly with respect to treatment with inhaled corticosteroids (Table II), and none of the children received antiviral agents. Forty-seven (72.3%) case patients had been treated with systemic steroids within the past week before enrollment. Prevalence of self-reported hay fever, atopy, family history of asthma, exposure to common allergens, and exposure to second-hand smoke did not differ significantly between the 2 groups (data not shown).

Case patients enrolled at the hospital and at the pulmonary clinic had comparable demographic features. There were no significant differences between these groups in recent use of medications, except ipratropium bromide (23.4% among hospitalized case patients vs 0% among

### TABLE II. Demographic and clinical characteristics of study participants

| Characteristics | Acute exacerbations (n = 65) | Well-controlled asthma (n = 77) | $P$ value |
|-----------------|-----------------------------|-------------------------------|----------|
| Age (y)         |                             |                               |          |
| <6              | 18                          | 19                            | 24.7     | NS       |
| 6-17            | 47                          | 58                            | 75.3     | NS       |
| Race/ethnicity  |                             |                               |          |
| Asian           | 1                           | 2                             | 2.6      | NS       |
| African American| 42                          | 31                            | 40.3     | .01*     |
| Hispanic/Latino | 1                           | 3                             | 3.9      | NS       |
| White           | 21                          | 41                            | 53.2     | NS       |
| Sex             |                             |                               |          |
| Female          | 30                          | 33                            | 42.9     | NS       |
| Male            | 35                          | 44                            | 57.1     | NS       |
| $\geq$3 health care provider visits for asthma in past 12 mo | 32 | 21 | 27.3 | <.01† |
| $\geq$2 hospital admissions for asthma in past 12 mo | 23 | 4 | 5.2 | <.001† |
| ICU admission for asthma ever | 30 | 13 | 16.9 | <.001† |
| $\geq$2 symptoms of respiratory infection at enrollment | 32 | 4 | 5.2 | <.001† |
| Medication use within past week‡ | | | |
| Short-acting $\beta$-agonists | 61 | 31 | 40.3 | <.001† |
| Ipratropium bromide | 11 | 1 | 1.3 | .001* |
| Inhaled corticosteroids | 40 | 56 | 72.7 | NS |
| Montelukast | 34 | 54 | 70.1 | .02‡ |

NS, No statistically significant difference; ICU, intensive care unit.
*Fisher exact test.
†$\chi^2$ Test.
‡Does not include medications for treatment given on the day of enrollment.
case patients treated at the clinic, \( P < .05 \). Hospitalized case patients were significantly more likely to have had 2 or more hospital admissions in the past 12 months (46.8\% vs 5.5\%; OR, 15.0; 95\% CI, 2.0-653.0), but there were no significant differences in the proportion of case patients with 3 or more health care provider visits for acute asthma treatment in the past 12 months and in the proportion of case patients ever admitted to the intensive care unit for asthma. The interval between the onset of asthma exacerbation and hospitalization or clinic visit for case patients was 7 or fewer days for 54 (91.5\%) of 59 patients who provided this information (median, 2 days).

PCR analysis of respiratory specimens was positive for 1 or more respiratory viruses in 41 (63.1\%) of the 65 asthmatic patients with acute exacerbations and in 18 (23.4\%) of 77 patients with controlled asthma (\( P < .001 \), \( \chi^2 \) test; Table III). Children with acute asthma exacerbations were nearly 6-fold more likely to have been infected with respiratory viruses than children with controlled asthma (OR, 5.6; 95\% CI, 2.7-11.6).

Results of PCR testing by agent are presented in Table III. Picornaviruses were identified in 54 participants. In 53 of 54 instances, picornavirus-positive specimens were confirmed positive for rhinoviruses, which were by far the most common respiratory viruses detected among study participants. In addition, 3 rhinovirus-positive specimens were also PCR positive with enterovirus-specific primers, indicating mixed infection. A picornavirus detected by means of PCR from 1 child in the control group could not be further characterized. Five children were positive for HMPV, 1 was positive for RSV, and 1 was positive for coronavirus E229. None of the participants were positive for human bocavirus, coronavirus OC43, HPVI 1 through 3, influenza viruses, or adenoviruses (Table III). Four children were coinfected with more than 1 respiratory virus: 3 children were positive for both rhinoviruses and enteroviruses, and the RSV-positive child was also positive for HMPV.

Of the 41 children with acute asthma who had positive PCR results for respiratory viruses, 21 (51.2\%) had 2 or more symptoms consistent with acute respiratory tract viral infection (median interval between onset of viral symptoms and specimen collection, 4 days). In the control group clinically manifested viral illness was present in 4 (22.2\%) of the 18 children with positive results for any respiratory virus. When the presence of symptoms of viral infection was taken into account, the association between asthma exacerbation and respiratory viruses was significant only for children with 2 or more symptoms of acute viral illness of the respiratory tract but not for children without clinically manifested viral infection (Table III). The association between the respiratory tract viral infections and asthma exacerbations remained significant after controlling for race/ethnicity, age, and season of testing (adjusted OR, 5.5; 95\% CI, 2.5-12.3).

For both case patients and control subjects, the prevalence of viral infection did not differ significantly among children aged 5 or fewer years versus children aged 6 to 17 years (Table IV). To assess the effect of asthma severity on the prevalence of viral infection, we analyzed the proportion of virus-positive children by using available surrogate indicators of overall asthma severity: number of health care provider visits and hospitalizations for asthma attacks in the past 12 months and past intensive care unit admissions for asthma. We found no indicator of asthma severity that significantly influenced the proportion of children with viral infections. However, the association between respiratory viruses and asthma exacerbations remained significant after controlling for race/ethnicity, age, and season of testing (adjusted OR, 5.6; 95\% CI, 2.7-11.6).
severity significantly associated with the prevalence of viral infection for case patients or control subjects (Table IV). Also, there were no significant differences between hospitalized and nonhospitalized case patients in the prevalence of respiratory viruses (55.6% vs 66.0%, $P > .05$) or symptomatic respiratory tract viral infections (39.0% vs 27.8%, $P > .05$).

For case patients, the potential effects of the use of systemic steroids within the past week, race, and intervals between the onset of symptoms of asthma exacerbation or the onset of viral infection and study enrollment on the rates of PCR positivity for respiratory viruses was further analyzed. No significant differences by any of these parameters were noted (Table V).

Because of the differences in montelukast use among case patients and control subjects and the paucity of data with regard to its potential effect on viral infections, we also analyzed virus positivity by montelukast use. For children with asthma exacerbation, 19 (55.4%) of the 34 specimens were positive for respiratory viruses among those who had received montelukast versus 22 (71%) among the 31 who had not. For the control group, the positivity rates were 20.4% (11/54) and 30.4% (7/23), respectively. The differences by montelukast use were not significant for either group. Other potentially relevant factors (eg, atopic status, use of inhaled corticosteroids, parental education level, family income, exposure to potential allergens at home, and family history of asthma) also did not affect the association between respiratory viruses and asthma exacerbations (data not shown).

Rhinovirus infections occurred throughout the year among both case patients and control subjects. For both groups, the highest overall activity was observed during April through June, accounting for 22 (41.5%) of the 53 rhinovirus detections (15 [38.5%] of the 39 detections

### TABLE IV. Proportion of children with respiratory viruses among case patients and control subjects by age group, health care provider visits, and hospital admissions for asthma in the past 12 months and intensive care unit admissions for asthma any time in the past

| Parameters                          | Acute exacerbations (n = 65) |          | Well-controlled asthma (n = 77) |          |
|-------------------------------------|------------------------------|----------|---------------------------------|----------|
|                                     | Total Virus (+)              | Total    | Virus (+)                       |          |
| Age group (y)                       | No. %                        | No. %    | No. %                           |          |
| 2-5                                 | 18 27.7                      | 10 55.6  | 19 24.7                         | 6 31.6   |
| 6-17                                | 47 72.3                      | 31 66.0  | 58 75.3                         | 12 20.7  |
| $P$ value                           | >.05*                        |          |                                 | >.05†    |
| Health care visits for asthma       |                             |          |                                 |          |
| in past 12 mo (n)                   | No. %                        | No. %    | No. %                           |          |
| 0-2                                 | 33 50.7                      | 18 54.4  | 56 72.7                         | 15 26.8  |
| $P$ value                           | >.05*                        |          |                                 | >.05†    |
| Hospital admissions for asthma      |                             |          |                                 |          |
| in past 12 mo (n)                   | No. %                        | No. %    | No. %                           |          |
| 0-1                                 | 42 64.6                      | 26 61.9  | 73 94.8                         | 17 23.2  |
| $P$ value                           | >.05*                        |          |                                 | >.05†    |
| ICU admission for asthma ever       |                             |          |                                 |          |
| Yes                                 | 30 46.2                      | 20 66.7  | 13 16.9                         | 2 15.4   |
| No                                  | 35 53.8                      | 21 61.8  | 64 83.1                         | 16 25.0  |
| $P$ value                           | >.05*                        |          |                                 | >.05†    |

ICU, Intensive care unit.

* $x^2$ Test.
† Fisher exact test.

### TABLE V. PCR positivity for respiratory viruses among patients with asthma exacerbations by steroid use within past week, race, and intervals between enrollment and onset of asthma exacerbation and viral symptoms

| Parameters                          | Total (n) | No. | Percent | $P$ value |
|-------------------------------------|-----------|-----|---------|-----------|
| Steroid use within past week        |           |     |         |           |
| Yes                                 | 47        | 31  | 66.0    | >.05*     |
| No                                  | 18        | 10  | 55.6    |           |
| Race                                |           |     |         |           |
| African American                    | 42        | 29  | 69.0    | >.05*     |
| Other                               | 23        | 11  | 47.5    |           |
| Interval between onset of viral symptoms and enrollment (d) | |     |         |           |
| $\leq$ 3                            | 16        | 11  | 68.8    | >.05†     |
| 4-7                                 | 9         | 6   | 66.7    |           |
| $>7$                                | 8         | 6   | 75.0    |           |
| Interval between onset of asthma exacerbation and enrollment (d) | |     |         |           |
| $\leq$ 3                            | 41        | 25  | 61.0    | >.05†     |
| 4-7                                 | 14        | 10  | 71.4    |           |
| $>7$                                | 5         | 4   | 65.0    |           |

* $x^2$ Test.
† $x^2$ Test for trend.
among case patients and 7 [50.0%] of the 14 detections among control subjects, Fig 1).

Ninety-one participants (33 [50.7%] case patients and 58 [75.3%] control subjects) were able to perform spirometry according to American Thoracic Society standards. FEV₁ was distributed toward significantly lower values among children with acute versus controlled asthma (P < .001, Fisher exact test). Mean FEV₁ in the 33 children with acute asthma was 75% of predicted value versus 94% of predicted value in the 58 children with well-controlled asthma (P < .001, unpaired Student t test). Twelve (36.4%) children with acute exacerbations of asthma had moderate-to-severe airway obstruction (FEV₁, <60% of predicted value) versus only 1 (1.7%) child with well-controlled asthma. The presence of virus in respiratory secretions was not associated with a reduction in FEV₁ among case patients (P > .05) and control subjects (P > .05).

**DISCUSSION**

In this study a high proportion of children with asthma had a rhinovirus detected in respiratory secretions, and rhinoviruses were the only respiratory viruses associated with asthma exacerbations. These results support the findings of previous investigators that acute exacerbations of asthma are significantly associated with rhinovirus infection in both children and adults.5,7,9,11,33,34

However, the association between rhinovirus infection and loss of asthma control was limited in this study to children with clinically manifested symptoms of a viral respiratory tract illness. There was a strong association between asthma exacerbation and symptomatic rhinovirus infections, and the extent of the difference between case patients and control subjects suggests that rhinoviruses might account for approximately 30% of asthma exacerbations in children. The overall rates of rhinovirus detection in our study for both case patients and control subjects were comparable with those reported in other studies of asthmatic patients.7-10,12,35

A number of factors could contribute to a role for rhinoviruses in asthma exacerbations, including their ability for replication in the cells of the lower airway tract; stimulate an inflammatory response that contributes to asthma exacerbations; or both.34 It is also possible that patients with asthma are more susceptible to rhinovirus infections. For example, a deficient immune response to rhinovirus infection, such as impaired type 1 cytokine production and defects in IFN-β previously described in asthmatic patients with atopy, might increase susceptibility to rhinovirus infection or impair clearance and result in more frequent or persistent rhinovirus.34,36-38

A substantial proportion of study participants (29.2% of case patients and 18.2% of control subjects) were infected with rhinoviruses but did not meet the study definition of symptomatic. Although the rate of rhinovirus positivity without accompanying acute respiratory illness was higher among case patients than among control subjects, this difference did not reach statistical significance. In a recent longitudinal study of healthy children, 20.6% of all rhinovirus infections were asymptomatic.39 In our study, the rate of rhinovirus infection in asthmatic children without clinically manifested acute viral illness was substantially higher: 47.8% for all rhinovirus-positive case patients and 100% for rhinovirus-positive control subjects. The basis for this high rate of rhinovirus infections without clinically apparent symptoms of acute respiratory illness in asthma is unclear but could indicate a high rate of persistent infections possible associated with a defect in ability to clear infection.

Rhinovirus infections have been associated with increased airway responsiveness and decreases in pulmonary function, although the latter has not been observed consistently among asthmatic patients or during experimental rhinovirus infections.11,40-45 In our study detection of rhinovirus RNA was not associated with a reduction in FEV₁ within either case patients or control subjects.
However, recent treatment with bronchodilators and corticosteroids received by study participants could have masked the effects of rhinovirus infection on lung function. Treatment received for asthma attacks before enrollment might explain the relatively low proportion (12/33 [36.4%]) of case patients with moderate-to-severe airway obstruction (FEV1, <60% of expected value).

Interestingly, although rhinoviruses are reported to have peak activity during the spring and fall,46 we found no statistically significant difference by season of the year in the rate of rhinovirus positivity in children with poorly controlled asthma, with rates of rhinovirus infection ranging from 50% to 71%, but for both case patients and control subjects, the highest level of rhinovirus activity was observed during spring months.

Although other studies have suggested that other respiratory viruses might also play a significant role in exacerbations of asthma,5,8,9,15,47 in the present study, using a panel of similarly sensitive PCR assays for 13 respiratory viruses, we only found an association between asthma exacerbations and rhinovirus. The seasonal, year-to-year, and geographic variability in activity levels for these respiratory viruses; differences in patient populations, specimen collection, or test methodologies; or both might have contributed to differences between our findings and those of other studies.

The relatively low prevalence of human RSV infection in our study is consistent with our exclusion of children younger than 2 years and with RSV being an important contributor to obstructive airway disease in children younger than 2 years of age but not older children. In addition, limiting enrollment to children with an established diagnosis of asthma eliminated children with transient wheezing episodes often caused by RSV. Similarly, limiting our study population to children older than 2 years might have also decreased HMPV detections in our study because most children appear to be infected with HMPV at a young age.48

It does not appear that influenza was a substantial contributor to asthma exacerbation in the Atlanta area during 2003 and 2004. The absence of influenza virus detections in our study can be explained by the shorter than usual duration of the 2003-2004 influenza season in the state of Georgia, which might have reduced its overall effect. According to the Georgia Division of Public Health surveillance data, the peak in influenza activity in the state was limited to a 3-week period in December (http://health.state.ga.us/epi/flu/fluupdall.asp). We might have missed influenza-positive children because of the small number of participants enrolled during the high-risk period (December enrollment, N = 8).

We did not detect the recently discovered human bocavirus22 in any of the study participants. Because bocavirus detections in asthmatic children have been reported,18,19 additional studies of potential association of this new virus with asthma are warranted.

Unlike many other studies of respiratory viruses in asthma, we collected respiratory secretions by using combined nasopharyngeal and throat swabs rather than nasal lavage specimens. Although it is possible that the use of swab instead of lavage specimens decreased our detection rates for some respiratory viruses, the potential loss in sensitivity with the swab was likely compensated for by the use of very sensitive PCR assays that have proved highly effective in other studies.57-49,50

A major strength of this study is use of a panel of very sensitive PCR assays for a full range of respiratory viruses. By enrolling patients over a full calendar year and frequency matching of case patients and control subjects by age and season of enrollment, we reduced potential biases associated with temporal and age-related differences in respiratory tract viral infections. Although there were certain differences in baseline characteristics between the case patients and control subjects (eg, by recent treatment, race/ethnicity, number of clinic visits, or hospitalizations for asthma in the past 12 months) that might have contributed to the differences in viral infection prevalence, none of these variables was significantly associated with rates of virus positivity and thus should not have confounded our findings.

One limitation of the present study is the modest sample size and corresponding limited ability to more carefully look at subgroups that might have clarified or identified new findings. Studies with larger numbers of patients and conducted over multiple years are needed to fully understand the role of all respiratory viruses in asthma exacerbations and to better define the association with rhinoviruses.

In summary, we found a strong association between symptomatic rhinovirus infections and asthma exacerbations. These results underscore the need for additional research to better characterize this association and suggest that future studies should investigate a role for antirhinovirus treatment or prevention as a strategy for decreasing disease burden associated with asthma.

We thank the study coordinators, Joanne Costolnick, Nick Raviele, and Eric Hunter from Emory Pediatrics, as well as Teresa Peret, Shannon Emory, Steve Oberste, and Silvia Peñaranda from the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, for performing some diagnostic testing. We also thank the physician members of the Sections of General Pediatrics and Critical Care Medicine, Egleston Children’s Hospital, who provided invaluable assistance with recruitment.

REFERENCES

1. Lambert HP, Stern H. Infective factors in exacerbations of bronchitis and asthma. BMJ 1972;3:223-7.
2. Minor TE, Dick EC, DeMeo AN, Ouellette JJ, Cohen M, Reed CE. Viruses as precipitants of asthmatic attacks in children. JAMA 1974; 227:292-8.
3. Clarke CW. Relationship of bacterial and viral infections to asthma. Thorax 1979;34:344-7.
4. Beasley R, Coleman ED, Hermon Y, Holst PE, O’Donnel TV, Tobias M. Viral respiratory tract infections and exacerbations of asthma. Thorax 1988;43:679-83.
5. Pattermore PK, Johnston SL, Bardin BG. Viruses as precipitants of asthma symptoms. I. Epidemiology. Clin Exp Allergy 1992;22:325-36.
6. Atmar RL, Guy E, Gunupalli KK, Zimmerman JL, Bandi VD, Baxter BD, et al. Respiratory tract viral infections in inner-city asthmatic adults. Arch Intern Med 1998;158:2453-9.
7. Johnston SL, Pattomoney PK, Sanderson G, Smith S, Lampre F, Josephs L, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225-38.
8. Rakes GP, Arruda E, Ingram JM, Hoover GE, Zambrano JC, Hayden FG, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care: IgE and eosinophil analysis. J Am J Respir Crit Care Med 1999;159:785-90.
9. Rawlinson WD, Wallaertsman Z, Carter JW, Belessis YC, Gilbert KM, Morton JR. Asthma exacerbations in children associated with rhinovirus and not human metapneumovirus infection. J Infect Dis 2003;187:1314-8.
10. Heymann PW, Carper HT, Murphy DD, Platts-Mills TA, Patrie J, McLaughlin AP, et al. Viral infections in relation to age, atopy and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol 2004;114:239-47.
11. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993;307:982-6.
12. Freymuth F, Vabret A, Brouard J, Toutain F, Verdon R, Petitjean J, et al. Detection of viral, Chlamydia pneumoniae, and Mycoplasma pneumoniae infections in exacerbations of asthma in children. J Clin Virol 1999;13:131-9.
13. Heymann PW, Platts-Mills TA, Johnston SL. Role of viral infections, atopy and antiviral immunity in the etiology of wheezing exacerbations among children and young adults. Pediatr Infect Dis J 2005;24(suppl):S217-22.
14. Oberste MS, Maher K, Schnurr D, Flemister MR, Lovchik JC, Peters H, et al. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J Gen Virol 2004;85:2577-84.
15. Williams JV, Crowe JE Jr, Enriquez R, Minton P, Peebles RS Jr, Hamilon RG, et al. Human metapneumovirus infection plays etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis 2005;192:1149-53.
16. Williams JV, Tolefson SJ, Heymann PW, Carper HT, Patrie J, Crowe JE. Human metapneumovirus infection in children hospitalized for wheezing. J Allergy Clin Immunol 2005;115:1311-2.
17. Fouloungne V, Rodiere M, Segondy M. Human bocavirus in children. Emerg Infect Dis 2006;12:862-3.
18. Ma X, Endo R, Ishiguro N, Ebihara T, Ishiko H, Ariga T, et al. Detection of human bocavirus in Japanese children with lower respiratory tract infections. J Clin Microbiol 2006;44:1132-4.
19. Johnston NW, Johnston SL, Norman GR, Dai J, Sears MR. The September epidemic of asthma hospitalization: school children as disease vectors. J Allergy Clin Immunol 2006;117:557-62.
20. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandel GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000. p. 1782-801.
21. Van den Hoogen BG, de Jong JC, Groot J, Kuijen T, de Groot R, Fouchier RA, et al. A newly discovered human metapneumovirus isolated from young children with respiratory tract disease. Nat Med 2001;7:719-24.
22. Allander T, Tummi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract sample. Proc Natl Acad Sci U S A 2005;102:12891-6.
23. Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, et al. Efficacy and safety of oral palonosetron for treatment of costs due to picornavirus in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003;36:1523-32.
24. Turner RB. New considerations in the treatment and prevention of rhinovirus infections. Pediatr Ann 2005;34:53-7.
25. Weinberger M. Respiratory infections and asthma: current treatment strategies. Drug Disc Today 2004;9:831-7.
26. Hankinson JL, Crapo RO, Jensen RL. Spirometric reference values for the 6-s FVC maneuver. Chest 2003;124:1805-11.
27. Erdman DD, Weinberg GA, Edwards KM, Walker FJ, Anderson BC, Winter J, et al. GeneScan reverse transcription-PCR assay for detection of six common respiratory viruses in young children hospitalized with acute respiratory illness. J Clin Microbiol 2003;41:4298-303.
28. Schrag SJ, Brooks JT, Van Beneden C, Parashar UD, Griffin PM, Anderson LJ, et al. SARS surveillance during emergency public health response, United States, March-July 2003. Emerg Infect Dis 2004;10:185-93.
29. Van Elden LJ, van Loon AM, van Alphen F, Hendriksen KA, Hoepleman AL, van Kraaij MG, et al. Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction. J Infect Dis 2004;189:652-7.
30. Lu X, Chittagangpith M, Olsen SJ, Mackay IM, Sloots TP, Fry AM, et al. Real-time PCR assays for detection of bocavirus in human respiratory tract samples. J Clin Microbiol 2006;44:3231-5.
31. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
32. Hosmer DW, Lemeshow S. Applied logistic regression, 2nd ed. New York: John Wiley & Sons, Inc; 2000. p. 133-4.
33. Johnston NW, Johnston SL, Duncan JM, Dau J, Sears MR. The Septem-ber epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol 2005;115:132-8.
34. Papadopoulos N, Papa A, Psarras S, Johnston SL, Mechanisms of rhinovi-rus-induced asthma. Pediatr Respir Rev 2004;5:255-60.
35. Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ 2002;324:763-6.
36. Wark PAB, Johnston SL, Bucchieri F, Powell R, Pudzicome S, Laza-styan V, et al. Aromatic bronchial epithelial cells have a deficient innate immune response to rhinovirus. J Exp Med 2005;201:937-47.
37. Kelly MJ, Marshall C, Smith S, Schreiber J, Sanderson G, Holgate ST, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet 2002;359:831-4.
38. Jartti T, Lehtinen M, Tuominen T, Koskenvuo M, Rasskauzen O. Persistence of rhinovirus and enterovirus RNA after acute respiratory illness in children. J Med Virol 2004;72:695-9.
39. Winter B, Hayden FG, Hendley JO. Picornavirus infections in children diagnosed by RT-PCR during longitudinal surveillance with weekly sampling: association with symptomatic illness and effect of season. J Med Virol 2006;78:644-50.
40. Genn JE, Calhoun W, Swenson C, Shen G, Busse WW. Rhinovirus infec-tion preferentially increases lower airway responsiveness in allergic subjects. Am J Respir Crit Care Med 1997;155:1872-6.
41. Zambrano JC, Carper HT, Rakes GP, Patrie J, Murphy DD, Platts-Mills TA, et al. Experimental rhinovirus challenges in adults with mild asthma: response to infection in relation to IgE. J Allergy Clin Immunol 2003;111:1008-16.
42. De Kuijper J, Evertse CE, Sont JK, SchrumplFJA, van Zelij-van der Ham CJ, Dick CR, et al. Are rhinovirus-induced airway responses in asthma aggravated by chronic allergen exposure? Am J Respir Crit Care Med 2003;168:1174-80.
43. Harju TH, Leenonen M, Nokso-Koivisto J, Korhonen T, Raty R, He Q, et al. Non-random distribution of pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma. Thorax 2006; Epub ahead of print.
44. Bardin PG, Fraenkel DJ, Sanderson G, van Schalkwyk EM, Holgate ST, Johnston SL, Peak expiratory flow changes during experimental rhinovi-rus infection. Eur Respir J 2000;16:980-5.
45. Venarski DL, Busse WW, Griffin MR, Gebretsadik T, Shintani AK, Minton PA, et al. The relationship of rhinovirus-associated asthma hospitalizations with inhaled corticosteroids and smoking. J Infect Dis 2006;193:1546-33.
46. Gwalney JM Jr. Rhinovirus. In: Mandel GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000. p. 1940-8.
47. Pelaa G, Vatrella A, Gallielli L, Renda T, Cazzola M, Maselli R, et al. Respiratory infections and asthma. Respir Med 2006;100:775-84.
48. Hamelin ME, Boivien G. Human metapneumovirus: a ubiquitous and long-standing respiratory pathogen. Pediatr Infect Dis J 2005;24(suppl):S203-7.
49. Carrat F, Leruez-Ville M, Tonnelier E, Deshayes J, Meyer P, et al. A virologic survey of patients admitted to a critical care unit for acute cardiorespiratory failure. Intensive Care Med 2006;32:156-9.
50. Griffin MR, Walker FJ, Iwane MK, Weinberg GA, Staat MA, Erdman DD, et al. Epidemiology of respiratory infections in young children: insights from the new vaccine surveillance network. Pediatr Infect Dis J 2004;23(suppl):S188-92.